The effectiveness of low-dose aspirin (LDA) in reducing adverse pregnancy outcomes
Atreca downsizes again to focus on antibody-drug conjugate programmes – Pharmaceutical Technology
Share this article Atreca reported $21.4m in cash reserves as of 30 September, with a net loss of $36.3m in Q3 2023. Image Credit: JHVEPhoto